The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of VS-6766 (RAF/MEK clamp) alone and in combination with defactinib (FAK inhibitor) in recurrent low-grade serous ovarian cancer (LGSOC).
 
Susana N. Banerjee
Honoraria - Amgen; AstraZeneca; Clovis Oncology; GlaxoSmithKline; Immunogen; Mersana; MSD Oncology; Pfizer; Roche; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca; GenMab; GlaxoSmithKline; Immunogen; Merck Serono; Mersana; MSD Oncology; OncXerna Therapeutics; Seagen; Shattuck Labs
Research Funding - AstraZeneca (Inst); GlaxoSmithKline (Inst)
 
Bradley J. Monk
Leadership - US Oncology
Honoraria - Agenus; Akeso Biopharma; Amgen; Aravive; AstraZeneca; Bayer; Clovis Oncology; Eisai; Elevar Therapeutics; EMD Serono/Merck; Genmab/Seattle Genetics; GOG Foundation; Gradalis; ImmunoGen; Iovance Biotherapeutics; Karyopharm Therapeutics; Macrogenics; Merck; Mersana; Myriad Pharmaceuticals; Novocure; Pfizer; Puma Biotechnology; Regeneron; Roche/Genentech; Sorrento Therapeutics; TESARO/GSK; US Oncology; Vascular Biogenics
Consulting or Advisory Role - Agenus; Akeso Biopharma; Amgen; Aravive; AstraZeneca; Bayer; Clovis Oncology; Eisai; Elevar Therapeutics; EMD Serono/Merck; Genmab/Seattle Genetics; GOG Foundation; Gradalis; Gradalis; ImmunoGen; Iovance Biotherapeutics; Karyopharm Therapeutics; Merck; Mersana; Myriad Pharmaceuticals; Novocure; Pfizer; Puma Biotechnology; Regeneron; Roche/Genentech; Sorrento Therapeutics; TESARO/GSK; US Oncology; Vascular Biogenics
Speakers' Bureau - AstraZeneca; Clovis Oncology; Eisai; Merck; Roche/Genentech; TESARO/GSK
Research Funding - Advaxis (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Genentech (Inst); Immunogen (Inst); Janssen (Inst); Lilly (Inst); Morphotek (Inst); Novartis (Inst); Nucana (Inst); Pfizer (Inst); Regeneron (Inst); Tesaro (Inst)
 
Els Van Nieuwenhuysen
No Relationships to Disclose
 
Kathleen N. Moore
Leadership - GOG Partners; NRG Oncology (Inst)
Honoraria - Great Debates and Updates; Physicans' Education Resource; Prime Oncology; Research To Practice
Consulting or Advisory Role - Alkermes (Inst); Aravive; AstraZeneca; Blueprint Medicines (Inst); Eisai; Genentech/Roche; GlaxoSmithKline/Tesaro (Inst); I-Mab (Inst); Immunogen; InxMed (Inst); Merck; Mereo BioPharma; Mereo BioPharma (Inst); Mersana (Inst); Myriad Genetics; Novartis; Onconova Therapeutics; OncXerna Therapeutics; TESARO (Inst); Vavotar Life Sciences; VBL Therapeutics
Research Funding - Abbvie/Stemcentrx (Inst); Advaxis (Inst); Agenus (Inst); Amgen (Inst); artios (Inst); AstraZeneca (Inst); Bayer (Inst); Bolt Biotherapeutics (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); cyteir (Inst); Daiichi Sankyo/Lilly (Inst); Forty Seven (Inst); Genentech (Inst); Immunocore (Inst); Immunogen (Inst); Lilly (Inst); Lilly Foundation (Inst); Merck (Inst); Novartis Pharmaceuticals UK Ltd. (Inst); Novogen (Inst); PTC Therapeutics (Inst); Regeneron (Inst); Stem CentRx (Inst); Takeda (Inst); Tesaro (Inst); Verastem (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
Other Relationship - GOG Partners (Inst)
 
Ana Oaknin
Consulting or Advisory Role - AGENUS; Amgen; AstraZeneca; Clovis Oncology; Corcept Therapeutics; Deciphera; Eisai; EMD Serono; Genmab; GlaxoSmithKline; Immunogen; ITeos Therapeutics; Medison; Merck Sharp & Dohme; Mersana; Novocure; PharmaMar; prIME Oncology; Roche; Roche; Shattuck Labs; Sutro Biopharma; Tesaro
Research Funding - Abbvie (Inst); Ability Pharma (Inst); Advaxis (Inst); Aeterna Zentaris (Inst); Agenus (Inst); Aprea Therapeutics (Inst); AstraZeneca (Inst); BeiGene (Inst); Belgian Gynaecological Oncology Group (Inst); Bristol-Myers Squibb International Corporation (BMS) (Inst); Clovis Oncology (Inst); Corcept Therapeutics (Inst); Eisai (Inst); Immunogen (Inst); Iovance Biotherapeutics (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Medimmune (Inst); Merck (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Mundipharma Research (Inst); Novartis Farmacéutica (Inst); Regeneron (Inst); Roche (Inst); Seagen (Inst); Seagen (Inst); Sutro Biopharma (Inst); Tesaro (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; PharmaMar; Roche
 
Michel Fabbro
Honoraria - AstraZeneca
Consulting or Advisory Role - AstraZeneca; Tesaro/GSK (Inst)
Travel, Accommodations, Expenses - Roche
 
Nicoletta Colombo
Employment - Sarepta Therapeutics (I)
Honoraria - Advaxis; Amgen; AstraZeneca; Clovis Oncology; Eisai; GlaxoSmithKline; Immunogen; mersana; MSD Oncology; Novartis; Nuvation Bio; Pfizer; Pfizer; Roche/Genentech; Tesaro
Consulting or Advisory Role - Advaxis; AstraZeneca; Clovis Oncology; Eisai; GlaxoSmithKline; Immunogen; mersana; MSD Oncology; Nuvation Bio; Pfizer; Pfizer; Roche/Genentech; Tesaro
 
David M. O'Malley
Consulting or Advisory Role - Abbvie; Agenus; Ambry Genetics; Arcus Biosciences; Arquer Diagnostics; AstraZeneca; Atossa Therapeutics; BBI Healthcare; Celsion; Clovis Oncology; Eisai; Elevar Therapeutics; Genelux; Genentech/Roche; GlaxoSmithKline; GOG Foundation; Immunogen; InxMed; Iovance Biotherapeutics; Janssen Oncology; Laekna Therapeutics; Leap Therapeutics; Marker Therapeutics; Myriad Genetics; Novartis; Novocure; Novocure; Onconova Therapeutics; OncoQuest; Regeneron; Roche; Rubius Therapeutics; Seagen; Sorrento Therapeutics; Sutro Biopharma; Takeda; Tarveda Therapeutics; Tesaro; Toray Industries; Translational Genomics Research Institute; VBL Therapeutics; Vincerx Pharma
Research Funding - Abbvie (Inst); Abbvie/Stemcentrx (Inst); Acerta Pharma (Inst); Advaxis (Inst); Ajinomoto (Inst); Ajinomoto (Inst); Amgen (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); AstraZeneca (Inst); BBI Healthcare (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Clovis Oncology (Inst); Deciphera (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Ergomed (Inst); Exelixis (Inst); Genentech/Roche (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Immunogen (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); Janssen Research & Development (Inst); Karyopharm Therapeutics (Inst); Leap Therapeutics (Inst); Ludwig Institute for Cancer Research (Inst); Merck (Inst); Mersana (Inst); Novartis (Inst); NovoCure (Inst); OncoQuest (Inst); Pfizer (Inst); PharmaMar (Inst); Precision Therapeutics (Inst); Regeneron (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Seagen (Inst); Sumitomo Dainippon Pharma Oncology, Inc. (Inst); Sutro Biopharma (Inst); Tesaro (Inst); TRACON Pharma (Inst); Verastem (Inst)
 
Robert L. Coleman
Employment - US Oncology
Leadership - Onxeo
Stock and Other Ownership Interests - McKesson
Consulting or Advisory Role - Abbvie; Abbvie/Stemcentrx; Agenus; Alkermes; AstraZeneca/MedImmune; Clovis Oncology; Genentech/Roche; Genmab; Gradalis; Immunogen; Merck; Merck; Novocure; Oncolytics; OncoMed; OncXerna Therapeutics; Regeneron; Sotio; Tesaro
Research Funding - Abbott/AbbVie; Amgen (Inst); Array BioPharma; AstraZeneca/MedImmune; Clovis Oncology; Esperance Pharmaceuticals; Immunogen (Inst); Johnson & Johnson; Lilly (Inst); Merck; Mirati Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst); Roche/Genentech
Travel, Accommodations, Expenses - Array BioPharma; AstraZeneca/MedImmune; Clovis Oncology; Clovis Oncology; GOG Foundation; Merck; Research to Practice; Roche/Genentech; Sotio; Vaniam Group
 
Amit M. Oza
(OPTIONAL) Uncompensated Relationships - Ozmosis Research
 
Jonathan A. Pachter
Employment - Verastem
Leadership - Verastem
Stock and Other Ownership Interests - Verastem
Patents, Royalties, Other Intellectual Property - Verastem
 
Gloria Patrick
Employment - Verastem
 
Louis J. Denis
Employment - Verastem
Leadership - Verastem
Stock and Other Ownership Interests - Verastem
Honoraria - Verastem
Consulting or Advisory Role - Verastem
Travel, Accommodations, Expenses - Verastem
 
Lorna Leonard
Stock and Other Ownership Interests - LabCorp; Sanofi
 
Rachel N. Grisham
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; GlaxoSmithKline; Mateon Therapeutics; Regeneron; Signatera
Research Funding - Context Therapeutics (Inst)
Travel, Accommodations, Expenses - EMD Serono
Other Relationship - Aptitude Health; MCM Education; OncLive; Prime Oncology
(OPTIONAL) Uncompensated Relationships - Verastem